M
Martin R Turner
Researcher at University of Oxford
Publications - 519
Citations - 40655
Martin R Turner is an academic researcher from University of Oxford. The author has contributed to research in topics: Amyotrophic lateral sclerosis & RNA-binding protein. The author has an hindex of 98, co-authored 503 publications receiving 34965 citations. Previous affiliations of Martin R Turner include University College London & Drexel University.
Papers
More filters
Journal ArticleDOI
Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav
Alexander Tarakhovsky,Martin R Turner,Stefan Schaal,P. J. Mee,L. P. Duddy,Klaus Rajewsky,Victor L. J. Tybulewicz +6 more
TL;DR: It is reported that antigen receptor-mediated proliferative responses of B and T cells in vitro are severely reduced in the absence of Vav, and a direct link between the low proliferative response of VAV-deficient B andT cells and the reduced number of these cells in peripheral lymphoid organs of chimaeric mice is suggested.
Journal ArticleDOI
Biomarkers in amyotrophic lateral sclerosis.
TL;DR: Potential biomarkers that are sensitive to the progression of disease, which might enhance the diagnostic algorithm and provide new drug targets, are now being identified from analysis of the blood and cerebrospinal fluid, as well as from neuroimaging and neurophysiology studies.
Journal ArticleDOI
Tyrosine kinase SYK: essential functions for immunoreceptor signalling
Martin R Turner,Edina Schweighoffer,Francesco Colucci,James P. Di Santo,Victor L. J. Tybulewicz +4 more
TL;DR: Gene-targeting studies have identified the cell types that require SYK for development and function, and the receptors that use SYK as well as their downstream signalling effectors.
Journal ArticleDOI
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
Ching-Hua Lu,Corrie Macdonald-Wallis,Elizabeth Gray,Neil Pearce,Axel Petzold,Niklas Norgren,Gavin Giovannoni,Pietro Fratta,Katie Sidle,Mark Fish,Richard W. Orrell,Robin S. Howard,Kevin Talbot,Linda Greensmith,Jens Kuhle,Martin R Turner,Andrea Malaspina +16 more
TL;DR: This report provides Class III evidence that the NfL electrochemiluminescence immunoassay accurately distinguishes patients with sporadic ALS from healthy controls and offers potential for N fL as a pharmacodynamic biomarker in future therapeutic trials.
Journal ArticleDOI
Cutting Edge: The Foxp3 Target miR-155 Contributes to the Development of Regulatory T Cells
Susan Kohlhaas,Oliver A. Garden,Cheryl L. Scudamore,Martin R Turner,Klaus Okkenhaug,Elena Vigorito +5 more
TL;DR: It is reported that miR-155-deficient mice have reduced numbers of Tregs, both in the thymus and periphery, due to impaired development, and that additional miRNAs control Treg function.